Cancer risk assessment begins with established screening, personal and family history, and careful consideration of which additional evaluation may be useful.
A risk-informed approach
Cancer is not a single disease, and no single test can reliably assess or exclude every form of cancer.
Wavepoint begins with personal and family history, prior screening, age, sex, exposures, inherited risk, existing medical conditions, and the recommendations of the member’s established clinicians. The objective is to identify important gaps, clarify individual risk, and support informed screening decisions.
Established screening comes first
Screening can identify certain cancers before symptoms appear, when treatment may be more effective. However, screening also carries potential harms, including false-positive findings, additional procedures, overdiagnosis, cost, and anxiety. The appropriate balance varies according to the individual and the test being considered.
Wavepoint emphasizes established, evidence-based screening appropriate to the member’s age, history, and risk. It does not use advanced testing as a substitute for recommended breast, colorectal, cervical, lung, prostate, skin, or other conventional evaluation.
Personal and inherited risk
Family history and patterns of cancer across generations may suggest the need for more individualized assessment.
When clinically appropriate, Wavepoint may recommend genetic counseling, hereditary cancer testing, specialist consultation, or screening that begins earlier or differs from routine population guidance. Genetic findings are interpreted in context and do not by themselves determine whether cancer will or will not develop.
Selected imaging and additional evaluation
Depending on individual risk, prior findings, and established care, selected imaging or other diagnostic evaluation may be considered.
These studies are not routine requirements for every member. Before recommending them, Wavepoint considers the likely value of the information, the possibility of incidental findings, the need for downstream testing, and whether the result is likely to change management.
Some evaluation is coordinated through independent laboratories, imaging centers, genetic counselors, and specialty clinicians.
Emerging methods
Blood-based multi-cancer detection tests and other emerging technologies may eventually expand cancer screening, but important questions remain regarding false-positive and false-negative results, overdiagnosis, follow-up, and whether their use reduces cancer mortality. They should be considered with appropriate caution and should not replace established screening.
Wavepoint may discuss selected emerging options when their potential benefits, limitations, and costs can be considered responsibly.
From screening to coordinated follow-through
The value of screening depends on what follows.
Wavepoint helps members understand recommendations and findings, identify appropriate next steps, and coordinate with primary care clinicians, radiologists, oncologists, surgeons, genetic counselors, and other specialists when needed.
Wavepoint does not diagnose or treat cancer as an oncology practice. Its role is to support thoughtful risk assessment, appropriate screening, interpretation, and coordination within the member’s broader medical care.
The scope is individualized
The breadth of cancer-risk assessment varies according to clinical history, family history, member priorities, existing care, and level of membership.
The goal is not to pursue every available test. It is to make informed decisions about which screening and diagnostic strategies are most likely to provide meaningful benefit.